Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

[1]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[2]  M. Heinrich,et al.  Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. , 2016 .

[3]  Y. Inaba,et al.  A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[4]  R. Salgia.  Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. , 2015, Future oncology.

[5]  P. Hall,et al.  Inhibition of Platelet-Derived Growth Factor Receptor α by MEDI-575 Reduces Tumor Growth and Stromal Fibroblast Content in a Model of Non-Small Cell Lung Cancer , 2013, Molecular Pharmacology.

[6]  R. Baffa,et al.  100 Inhibition of PDGFRalpha in tumor stroma with MEDI-575 enhances activity of carboplatin/paclitaxel and delays tumor regrowth in a NSCLC xenograft model , 2010 .

[7]  J. Bauman,et al.  Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations , 2007, Clinical Cancer Research.

[8]  U. Eriksson,et al.  The PDGF family: four gene products form five dimeric isoforms. , 2004, Cytokine & growth factor reviews.

[9]  S. Phuphanich,et al.  Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma , 2016, Journal of Neuro-Oncology.